Immunologic checkpoints in cancer therapy: Focus on the programmed death-1 (PD-1) receptor pathway

Pharmacogenomics and Personalized Medicine

Volumn 7, Issue , 2014, Pages 357-365

  Momtaz, Parisa ^a,b   Postow, Michael A ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cytotoxic T lymphocyte antigen 4; Immune checkpoints; Immunotherapy; Programmed cell death protein 1

Indexed keywords

AMP 224; ANTINEOPLASTIC AGENT; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; DURVALUMAB; GLYCOPROTEIN GP 100; GLYCOPROTEIN GP 100 VACCINE; IPILIMUMAB; MCX 1105; MPDL 3280A; MSB 0010718C; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; RITUXIMAB; SIPULEUCEL T; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADAPTIVE IMMUNITY; ADRENAL INSUFFICIENCY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLITIS; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DECREASED APPETITE; DERMATITIS; DIARRHEA; DISEASE MARKER; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; FATIGUE; FOLLICULAR LYMPHOMA; HEAD AND NECK CANCER; HEPATITIS; HODGKIN DISEASE; HUMAN; HYPERTHYROIDISM; HYPERTRANSAMINASEMIA; HYPOTHYROIDISM; IMMUNE RESPONSE; IMMUNOREGULATION; INNATE IMMUNITY; KIDNEY CARCINOMA; LYMPHOCYTE ACTIVATION; MELANOMA; MULTIPLE MYELOMA; NAUSEA; NEPHRITIS; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PANCREATITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRURITUS; RASH; RECURRENCE FREE SURVIVAL; RETREATMENT; REVIEW; SOLID TUMOR; STOMACH CANCER; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR MICROENVIRONMENT;

EID: 84924902841     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S53163     Document Type: Review

References (53)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
2. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med. 2012;366(26):2517-2519.
3. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10.
4. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329-360.
5. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117(5):1137-1146.
6. Raval RR, Sharabi AB, Walker AJ, Drake CG, Sharma P. Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer. 2014;2:14.
7. Kantoff PW, Higano CS, Shore ND, et al; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-422.
8. Postow M, Callahan MK, Wolchok JD. Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. Cancer J. 2011;17(5):372-378.
9. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7-17.
10. Kirkwood JM, Manola J, Ibrahim J, et al; Eastern Cooperative Oncology Group. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10(5):1670-1677.
11. Sullivan RJ, Lorusso PM, Flaherty KT. The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res. 2013;19(19):5283-5291.
12. O’Day S, Boasberg P. Management of metastatic melanoma 2005. Surg Oncol Clin N Am. 2006;15(2):419-437.
13. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
14. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell. 1992;71(7):1065-1068.
15. Egen JG, Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity. 2002;16(1):23-35.
16. Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25(21):9543-9553.
17. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immu­nity by CTLA-4 blockade. Science. 1996;271(5256):1734-1736.
18. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipula­tion in tumor immunotherapy. Annu Rev Immunol. 2001;19:565-594.
19. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465.
20. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoin­hibitory receptor by a novel B7 family member leads to negative regula­tion of lymphocyte activation. J Exp Med. 2000;192(7):1027-1034.
21. Shin T, Yoshimura K, Shin T, et al. In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. J Exp Med. 2005;201(10):1531-1541.
22. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439(7077):682-687.
23. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793-800.
24. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851-862.
25. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37.
26. Marzec M, Zhang Q, Goradia A, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A. 2008;105(52): 20852-20857.
27. Atefi M, Avramis E, Lassen A, et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res. 2014;20(13):3446-3457.
28. Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13(1):84-88.
29. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. Epub April 8, 2014.
30. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
31. Robert, C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarba­zine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-2526.
32. Wolchok JD, Weber JS, Maio M, et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol. 2013;24(8):2174-2180.
33. Wolchok JD, Joos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-7420.
34. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013;19(19):5300-5539.
35. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167-3175.
36. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454.
37. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020-1030.
38. Weber JS, Kudchadkar RR, Yu B, et al. Safety, efficacy, and biomark­ers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma. J Clin Oncol. 2013;31(34):4311-4318.
39. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-133.
40. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134-144.
41. Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and phar­macokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008;14(10):3044-3051.
42. Armand P, Nagler A, Weller EA, et al. Disabling immune tolerance by pro­grammed death-1 blockade with pidilizumab after autologous hematopoi­etic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013;31(33):4199-4206.
43. Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014;15(1):69-77.
44. Hamid O, Sosman JA, Lawrence DP, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic melanoma. J Clin Oncol. 2013;31 (Suppl) [abstr 9010].
45. Spigel DR, Gettinger SN, Horn L, et al. Clinical activity, safety and biomarkers of MPDL3208A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2013;31 (Suppl) [abstr 8008].
46. Cho DC, Sosman JA, Sznol K, et al. Clinical activity, safety and bio­markers of MPDL3208A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (RCC). J Clin Oncol. 2013;31 (Suppl) [abstr 4505].
47. Lutzky J, Antonia SJ, Blake-Haskins A, et al. A phase I study of MEDI4736, an anti-PD-L1 antibody, in patients with solid tumors. J Clin Oncol. 2014;32:5s (Suppl) [abstr 3001].
48. Segal NH, Antonia SJ, Brahmer JR, et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. J Clin Oncol. 2014;32:5s (Suppl) [abstr 3002].
49. Heery CR, O’Sullivan Coyne GH, Madan RA, et al. Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies. J Clin Oncol. 2014;32:5s (Suppl) [abstr 3064].
50. Infante JR, Powderly JD, Burris HA, et al. Clinical and pharma­codynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor. J Clin Oncol. 2014;31 (Suppl) [abstr 3044].
51. Robert, C, Schadendorf D, Messina M, Hodi FS, O’Day S; MDX010-20 investigators. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res. 2013;19(8):2232-2239.
52. Lipson, E.J, Sharfman WH, Drake CG, et al. Durable cancer regres­sion off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2013;19(2):462-468.
53. Hino, R, Kabashima K, Kato Y, et al. Tumor cell expression of pro­grammed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010;116(7):1757-1766.